Sign In
Buy HROW
$33.32
+0.460 (+1.40%)
At Close: Jun 03, 2026
Harrow: Hedge Downside Risk With The 11.5% Yielding Baby Bonds
03:26am, Monday, 05'th Feb 2024
Harrow has two outstanding notes on offer that come up for maturity in 2026 and 2027. The 11.875% Senior Notes due 2027 offer a compelling 11.5% yield on cost and trade at a just under 3% premium to t
Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
04:03pm, Tuesday, 30'th Jan 2024
Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
Harrow Announces New Appointments to its Board of Directors
07:00am, Monday, 29'th Jan 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointments of Adrienne Graves, Ph.D., and Lauren Silvernail to
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non
Harrow Partners with Leading Healthcare Market Access Technology Platforms
07:00am, Wednesday, 03'rd Jan 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it has partnered with three leading healthcare technology platfo
7 Short-Squeeze Stocks That Are Screaming for Speculation
01:08pm, Sunday, 24'th Dec 2023
While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it's time to address this speculative p
Harrow Completes Transfer of the TRIESENCE® New Drug Application
07:00am, Wednesday, 29'th Nov 2023
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application
New Strong Sell Stocks for November 14th
08:16am, Tuesday, 14'th Nov 2023
AKZOY, GTX and HROW have been added to the Zacks Rank #5 (Strong Sell) List on November 14, 2023.
Harrow, Inc. (HROW) Q3 2023 Earnings Call Transcript
09:25pm, Monday, 13'th Nov 2023
Harrow, Inc. (NASDAQ:HROW ) Q3 2023 Earnings Conference Call November 13, 2023 4:45 PM ET Corporate Participants Jamie Webb - Director-Communications & Investor Relations Mark Baum - Chief Executive O
Harrow Health's 5-Year Guidance
04:14pm, Wednesday, 27'th Sep 2023
Harrow Health has guided to at least $1 billion in revenue by 2027 based on their current portfolio of drugs. The company's deep moat and strong customer relationships make it possible for them to acq
Harrow Health, Inc. (HROW) Q2 2023 Earnings Call Transcript
10:35pm, Wednesday, 09'th Aug 2023
Harrow Health, Inc. (NASDAQ:HROW ) Q2 2023 Earnings Conference Call August 9, 2023 4:45 PM ET Company Participants Jamie Webb - Director-Communications & Investor Relations Mark L. Baum - Chief Execut
Harrow Health And Its Interesting 11.6% 2027 Baby Bond
11:00am, Tuesday, 01'st Aug 2023
Harrow Health is an eye care pharmaceuticals company. The common stock has been on fire with expectations of rapidly increasing profits. HROW has 2 baby bonds, with one looking particularly interestin
Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength?
12:09pm, Thursday, 20'th Jul 2023
Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
Why Shares of Harrow Health Are Jumping Wednesday
12:17pm, Wednesday, 19'th Jul 2023
Harrow added seven new products through an acquisition. The company said it expects increased revenue year over year in the second quarter.
Harrow Health (HROW) Flat As Market Sinks: What You Should Know
07:25pm, Friday, 23'rd Jun 2023
Harrow Health (HROW) closed at $18.52 in the latest trading session, marking no change from the prior day.
